Clinical Trial Update: A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update: Merus B.V. is evaluating Petosemtamab in combination with pembrolizumab versus pembrolizumab alone as first-line therapy for head…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Petosemtamab

Snippet

Sponsor: Merus B.V. | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING